Your Sorted CME/CE Activities

Therapeutic Advances for Castration Resistant Prostate Cancer: Updates from the 2015 American Society of Clinical Oncology Annual Meeting
Certified CME - Mini Modules
Advances in cancer research unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Mini Modules will review data on castration resistant prostate cancer (CRPC) presented at the 2015 ASCO. Clinical trial data gives new insight into the timing and scheduling of currently approved agents for CRPC. In addition, investigational approaches to CRCP will be presented, as well as information relating to biomarkers and other methods of guiding day-to-day clinical decision-making in this tough-to-treat population.
Review one or all Mini Modules of interest. Each activity has been approved
for 0.5 AMA PRA Category 1 Credits™. Credits may be claimed
after completion of a brief Post-Test/Evaluation.
Michael A. Carducci, MD, FACP, FASCO
Michael A. Carducci, MD, FACP, FASCO
AEGON Professor in Prostate Cancer Research
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The Johns Hopkins University School of Medicine




*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings of the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
20
Supported by an independent educational grant from Bayer Healthcare
Expired Activity
Mini Module
6067
ASCO_WebBanner1150x108.gif
Hem-Onc